MGMT and neoplasm: Thus, the presence or absence of MGMT is considered a prognostic factor for GBM patients, as tumor cells with epigenetic silencing of the MGMT promoter (i.e., MGMT-methylated) are more susceptible to DNA damage than those that express MGMT (i.e., MGMT-unmethylated) [6, 8, 9].